Could a gut bacteria byproduct help tame fatty liver in type 1 diabetes?
NCT ID NCT07684248
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This trial investigates whether a supplement called butyrate (a substance produced by gut bacteria) and an intensive lifestyle program (Mediterranean diet plus exercise) can reduce liver fat in adults with type 1 diabetes who also have fatty liver disease. Participants are randomly assigned to one of four groups: standard advice plus placebo, lifestyle changes plus placebo, butyrate alone, or both butyrate and lifestyle changes. The study measures changes in liver fat using a special ultrasound-like scan, along with blood sugar control and other health markers over six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sodium butyrate (microencapsulated)
- What this could lead to
- If effective, this could offer a simple, low-cost way to manage fatty liver disease in people with type 1 diabetes, where few treatment options exist.
- What could go wrong
- This is a mid-sized early-stage trial, and the benefits seen may not be large or lasting. Butyrate supplements can cause mild digestive upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Regional Universitario de Málaga, FIMABIS
Málaga, Málaga, 29009, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sleep apnea may signal hidden liver trouble
- Three telehealth sessions could ease the burden of type 1 diabetes on families
- Menstrual cycle timing may change how exercise impacts blood sugar in type 1 diabetes
- Can screening for social needs improve diabetes care for kids?
- Could a diabetes drug turn back the biological clock in HIV?
- Fatty liver may be a hidden driver of heart attacks in diabetes